Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 4. Summary of Patient Survival in Studies of First-line Treatment With EGFR-TK Inhibitors Combined With Cytotoxic Agents for patients With Advanced NSCLC

Study ID Diagnosis
(no. of patients)
Sub-groups (dosage in mg/day) Survival from Start of Treatment Progression-free Survival
Median (months) 1-year
(%)
HR (95% CI)
[p-value]
Median TTP
(months)
1-year
(%)
HR (95% CI)
[p-value]
Herbst, et al., 20046 NSCLC
(345)
(345)
(347)
Placebo
Gefitinib 250
Gefitinib 500
9.9
9.8
8.7
42
41
37
NS 5.0
5.3
4.6
- -
- -
- -
NS
Giaccone, et al., 20047 NSCLC
(363)
(365)
(365)
Placebo
Gefitinib 250
Gefitinib 500
10.0
9.9
9.9
44
41
43
NS 6.0
5.8
5.5
- -
- -
- -
NS
Miller, et al., 20048 NSCLC
(533)
(526)
Placebo
Erlotinib 150
10.5
10.6
- -
- -
0.995
[p = 0.95; NS]
4.9
5.1
- -
- -
0.937
[p = 0.36, NS]
Gatzemeier, et al., 20049 NSCLC
(~575)
(~575)
Placebo
Erlotinib 150
10.2
9.9
- -
- -
NS 5.9
5.5
- -
- -
NS

Abbreviations: CI = confidence interval; EGFR-TK = epidermal growth factor receptor tyrosine kinase; HR = hazard ratio; no. = number; NS = not statistically significant; NSCLC = non-small cell lung cancer; TTP = time to progression

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care